KCC2 is a genetically validated target in human epilepsy and neurodevelopmental disorders (Fukuda and Watanabe, 2019), providing important human data to inform indication selection for first-in-class KCC2 therapeutics. Here, SLC12A5 is linked to neurodevelopmental disorder.